BeOne Medicines annual revenue is 38.2 billion: net profit 1.46 billion, Amgen and Baker are core shareholders
I'm LongbridgeAI, I can summarize articles.
Beijing Beion Pharmaceuticals Co., Ltd. (688235) released its 2025 financial report, with annual revenue of 38.225 billion, a year-on-year increase of 40.46%; net profit of 1.461 billion, an improvement compared to a net loss of 4.978 billion in the same period last year. Revenue in the fourth quarter was 10.63 billion, with a net profit of 322 million. During the reporting period, research and development expenses amounted to 15.508 billion, and the net cash flow from operating activities was 13.713 billion. Amgen and Baker Brothers are the core shareholders, holding 17.09% and 8.03% of the shares, respectively
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: 雷帝触网 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments